New Ultra-Sensitive Assays Aim to Improve Early Detection of Alzheimer’s and Parkinson’s Disease
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Siemens Healthineers has introduced two new blood-based tau assays for research use on the Atellica platform, expanding its brain health portfolio with tests aimed at advancing neurodegenerative disease research.
A University of Warwick study finds AI cancer detection models may rely on statistical correlations rather than true biomarker signals, raising concerns about reliability in clinical pathology applications.
The FDA has granted Breakthrough Device Designation to PathAI’s PathAssist Derm, an AI-powered tool designed to analyze digital pathology images of skin lesions and assist pathologists in diagnostic review.
Philips has launched a cloud-based version of its IntelliSite Pathology Solution on AWS, enabling labs to scale digital workflows and manage high-resolution pathology images without on-premise infrastructure, according to the company.
The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
A Duke-led study reports that measuring piRNAs in blood samples predicts two-year survival in older adults with up to 86% accuracy, outperforming traditional health indicators, according to findings published in Aging Cell.
QuidelOrtho has signed a supply agreement with Lifotronic to add multiple analyzer platforms and over 25 new immunoassays, expanding its testing portfolio in international markets outside the US.
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
The exsig Mag RapidBead Pro kit features a four-step workflow that reduces extraction time to under 20 minutes.
The Phase 2 grant supports AI-driven analysis of retinal tissue to identify disease-specific patterns linked to ALS, FTD, and LATE.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
New recommendations address evolving drug landscape and advancing testing technologies since original 2003 guidance.